Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy
Ontology highlight
ABSTRACT: Genetic polymorphisms in the region of the trimeric serine hydrolase HTRA1 are associated with increased risk of age-related macular degeneration (AMD) and disease progression, but the precise biological function of HtrA1 in the eye and its contribution to disease etiologies remains undefined. In this study, we have developed an HtrA1 blocking Fab fragment to test the therapeutic hypothesis that HtrA1 protease activity is involved in the progression of AMD. Next, we generated an activity-based small molecule probe (ABP) to track target engagement in vivo. In addition, we used N-terminomic proteomic profiling in pre-clinical models to elucidate the in vivo repertoire of HtrA1 specific substrates, and identified substrates that can serve as robust pharmacodynamic biomarkers of HtrA1 activity. One of these HtrA1 substrates, Dickkopf related protein 3 (DKK3), was successfully used as a biomarker to demonstrate the inhibition of HtrA1 activity in patients with AMD that were treated with the HtrA1 blocking Fab fragment. To our knowledge, this is the first pharmacodynamic biomarker measuring ocular protease activity in AMD.
INSTRUMENT(S): Orbitrap Fusion Lumos, LTQ Orbitrap Elite
ORGANISM(S): Macaca Fascicularis (ncbitaxon:9541) Oryctolagus Cuniculus (ncbitaxon:9986)
SUBMITTER: Jennie Lill
PROVIDER: MSV000084831 | MassIVE | Wed Jan 22 13:01:00 GMT 2020
REPOSITORIES: MassIVE
ACCESS DATA